SCHEDULE: AIGH Capital Management Maintains 9.9% Stake in Aprea Therapeutics

AIGH Capital Management LLC and Orin Hirschman reported a 9.9% beneficial ownership stake in Aprea Therapeutics, Inc. common stock as of December 31, 2025.

Summary

• Orin Hirschman, AIGH Capital Management LLC, and AIGH Investment Partners LLC are the Reporting Persons.
• The filing is an Amendment No. 3 to Schedule 13G for Aprea Therapeutics, Inc. (Issuer).
• The class of securities is Common Stock, $0.001 par value per share, with CUSIP Number 03836J102.
• The Reporting Persons collectively beneficially own 651,747 shares, representing 9.9% of the class.
• This aggregate amount includes 281,206 common shares issuable upon the exercise of warrants.
• Orin Hirschman and AIGH Capital Management LLC each hold sole voting power over 370,541 shares.
• Orin Hirschman and AIGH Capital Management LLC each hold sole dispositive power over 651,747 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine disclosure of beneficial ownership by an institutional investor, indicating a continued significant stake without suggesting any immediate positive or negative operational news for the issuer.

Positives

• A significant institutional investor, AIGH Capital Management, maintains a substantial stake (9.9%) in Aprea Therapeutics, indicating continued confidence.
• The acquisition of securities is stated to be in the ordinary course of business, suggesting a passive investment strategy rather than an activist one aimed at control.

Future Outlook

NA

Management Comments

• Orin Hirschman certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor and does not provide specific industry context or analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake (9.9%) by AIGH Capital Management may provide a level of confidence or stability, as it indicates a notable investor's continued interest in Aprea Therapeutics.

Key Dates

Keywords

Aprea Therapeutics, AIGH Capital Management, Orin Hirschman, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Investment Advisor